IXICO PLC (LSE:IXI, OTC:PHYOF) CEO Bram Goorden takes Proactive's Stephen Gunnion through the company’s full-year 2025 results and its outlook for 2026. Goorden confirmed a 13% increase in revenue to £6.5 million, driven by diversification into new trials in Alzheimer’s and Parkinson’s disease, contract extensions with existing clients, and expansion into blood-based biomarkers and diagnostics. He highlighted that this strategic focus has already led to a new win in Alzheimer’s disease after the reporting period. Looking forward, Goorden said the company is forecasting £7.5 million in revenue for full-year 2026, representing 15% growth, and expects gross margins to exceed 50%. A key driver of future performance will be IXICO’s continued investment in technology. “Especially that integration space… we are looking at how we can start to integrate the IXIQ platform with some of these major players that we are partnering with,” he said. Automation and platform integration with larger data and CRO platforms are seen as pivotal in scaling operations. Goorden reaffirmed IXICO’s commitment to the central nervous system (CNS) space, stating, “We very much believe in this focus strategy, and it’s actually what makes us also that global leader in that space.” Watch the full interview to learn more about IXICO’s strategy and market outlook. For more company interviews, visit Proactive's YouTube channel. Don’t forget to like, subscribe, and enable notifications to stay updated. #IXICO #BramGoorden #BiotechStocks #Neuroscience #AlzheimersResearch #ParkinsonsDisease #CRO #HealthcareInvesting #Biomarkers #LifeSciences #MedicalImaging #InvestorUpdate #AIinHealthcare #ClinicalTrials #ProactiveInvestors
